Five things to know about cystic acne treatment
Structured for search, voice, and AI-overview extraction. These are the most frequent first-question answers for patients arriving with severe nodulocystic acne — answered before the full clinical education begins.
Who should read this cystic acne page
Cystic acne is treated as severe disease — it is not a phase to wait out, and it is not the same problem as ordinary teenage pimples. The patients below benefit most from the detail on this page. If you are managing comedonal or mild inflammatory acne, the broader parent acne hub covers your situation more directly.
Adults with deep painful nodules
Tender lumps several millimetres below the surface, often on the lower face, jawline, chin, or upper trunk, that take weeks to settle and frequently leave a mark or a depression behind.
Patients with active scar formation
If photographs from week to week show new ice-pick, boxcar, rolling, or hypertrophic scars forming, escalation is no longer optional. Cystic disease that scars on photographs is severe by definition.
Recurrent cysts in the same area
Repeated cysts in the same anatomical zone — same cheek, same jaw — point to deeper follicular and sebaceous involvement than ordinary acne, and almost always need a different plan than another antibiotic course.
Patients evaluating isotretinoin
Patients considering oral isotretinoin (or whose dermatologist has raised it) need plain-language detail about candidacy, baseline investigations, the contraception protocol for women of reproductive age, and what monitoring looks like over the months of treatment.
Patients before a wedding or major event
A single large painful cyst before a wedding, exam, surgery, or family event has a specific solution — a small intralesional triamcinolone injection that flattens it within 24–72 hours. This is an adjunct, not a routine treatment, and the protocol is laid out below.
Patients with prior treatment failures
Patients who have completed multiple antibiotic courses, tried several over-the-counter regimens, or had short bursts of clearance followed by relapse — the right next step is a fresh assessment, not the next antibiotic, and this page explains what changes.
How cystic acne presents on the skin
Cystic acne has a recognisable clinical signature that distinguishes it from ordinary inflammatory acne. The lesions are deeper, the pain is greater, the time course is longer, and the scar risk is higher. Correctly identifying the pattern is the first clinical step.
Nodules
Firm, tender, deeply seated lumps that sit several millimetres below the skin surface. They can be the size of a pea or larger, persist for weeks, and produce dull aching pain even before they become visible. Squeezing damages dermal tissue and worsens scar risk significantly.
Cysts
Fluid-filled lesions deeper than ordinary pustules. They may feel soft and fluctuant, or firm and indurated when inflammation is at its peak. The fluid is a mixture of sebum, keratin debris, dead inflammatory cells, and bacteria — not pus that should be drained at home.
Sinus tracts
Connected channels between adjacent cysts under the skin. Patients describe one cyst draining and another swelling next to it. Sinus tracts are a feature of severe nodulocystic disease and an indication for systemic therapy in most cases.
Scar formation
Depressed scars (ice-pick, boxcar, rolling) form as the dermal collagen damaged by deep inflammation fails to repair to original architecture. Hypertrophic and keloidal scars can form on the chest, back, and jawline. Both are largely preventable by treating cystic acne early.
Post-inflammatory hyperpigmentation
Flat dark or greyish marks left after a cyst settles. In Indian skin (Fitzpatrick III–V) these marks are darker, larger, and slower to fade than in lighter skin types because melanocytes respond more vigorously to inflammation. PIH is not a scar; it is a pigment change and improves over months with sun protection and correct care.
Distribution
Lower face, jawline, neck, chest, upper back, and shoulders are the highest-density sebaceous zones and the most commonly affected sites. In adult women, a lower-face / chin / jaw distribution that flares cyclically before menstruation is characteristic of a hormonal driver.
Red-flag features that escalate urgency
- Multiple cysts that connect under the skin — sinus tracts indicate disease severity that topical-only therapy cannot reach.
- Scars visible on photographs from one month to the next — scar formation in real time is the strongest indication for systemic therapy.
- Cysts in the same area despite repeated antibiotic courses — suggests an underlying driver that antibiotics alone cannot solve.
- Severe pain interfering with sleep, work, or eating — pain at this level reflects deep dermal inflammation and merits faster review.
- Sudden onset with fever, malaise, or joint pain — possible acne fulminans; needs urgent dermatological assessment.
- Worsening despite a complete adherent regimen at six weeks — six weeks is enough to judge initial response; further worsening means escalation.
Why cystic acne forms — the four-factor model
Cystic acne is the same biological process as ordinary acne taken to a deeper, more inflammatory extreme. Four factors interact in every lesion: excess sebum from sebaceous glands, abnormal keratinocyte shedding inside the follicle, proliferation of Cutibacterium acnes, and an immune response that progresses from contained inflammation into dermal damage.
In ordinary acne, this process produces small papules and pustules that resolve over days. In cystic acne the follicle ruptures deeper in the dermis, the immune response is more intense, the surrounding tissue is more involved, and the resolution takes weeks. Scar tissue is the marker that the body has been unable to repair the damage to the original architecture.
The reason some patients develop cystic disease and others do not is not fully understood, but several factors are recognised contributors. Genetic predisposition matters — first-degree relatives of patients with severe cystic acne have a measurably higher risk. Androgen activity matters; in adult women, hormonal patterns (PCOS, polycystic ovary morphology, perimenopause) are over-represented in nodulocystic distributions on the lower face. Skin type matters; very thick, oily, sebaceously rich Fitzpatrick III–V skin tends to support deeper follicular plugging.
Environmental and behavioural factors compound the underlying biology. Topical steroid mixtures sold over the counter for "fairness" or rashes commonly cause a steroid-induced rosacea-like nodulocystic eruption. Heavy hair oils and pomades create comedonal load on the forehead and temples. High-glycaemic diets and certain dairy patterns aggravate sebaceous activity in susceptible individuals. Stress, through cortisol and androgen pathways, raises sebum output and inflammatory cytokine production. None of these are causes of acne in someone without underlying sebaceous predisposition — they are aggravators that can shift moderate disease into severe, or delay clearance once treatment is started.
The deep inflammatory cascade
- Androgens drive sebaceous glands into overproduction.
- Follicular keratinocytes shed abnormally and form a plug.
- Sebum and dead cells accumulate behind the plug; the follicle distends.
- C. acnes proliferates in the lipid-rich anaerobic environment.
- Bacterial lipases and proteases damage the follicular wall.
- The wall ruptures into the dermis, releasing contents into surrounding tissue.
- Neutrophils, lymphocytes, and macrophages recruit en masse.
- The dermis is damaged faster than it can be repaired — scar architecture forms.
Recognised aggravators
- Topical steroid mixtures (combination "fairness" or "rash" creams).
- Anabolic steroids and certain bodybuilding supplements.
- Lithium, ciclosporin, certain anti-epileptics, EGFR inhibitors.
- Hormonal contraceptive change (initiation or discontinuation).
- PCOS and elevated free androgens in adult women.
- High-glycaemic diet patterns and certain dairy patterns in susceptible individuals.
- Heavy occlusive hair oils and comedogenic cosmetics.
- Chronic stress through cortisol and androgen mediation.
- Sweat, friction, and humidity (gym, occupational, monsoon).
How a dermatologist diagnoses and grades cystic acne
Cystic acne is a clinical diagnosis. There is no laboratory test that confirms it, but the consultation gathers the structured information needed to grade severity, identify drivers, and choose the right treatment ladder. A consultation lasting fifteen rushed minutes is not enough for severe disease; expect a full assessment.
What the dermatologist examines
- Lesion type, depth, and distribution across face, chest, and back.
- Number of comedones, papules, pustules, and nodules per zone.
- Active scar formation — colour, texture, depth.
- Post-inflammatory hyperpigmentation pattern and severity.
- Skin type (Fitzpatrick III–V is most relevant to Indian patients).
- Barrier status — dryness, irritation, prior product damage.
- Hair pattern (hirsutism, androgenetic features) in adult women.
What the history covers
- Onset, duration, and trajectory of cystic disease.
- Menstrual pattern and PCOS investigation history (women).
- Prior topical, oral, and procedural acne treatments and their results.
- Steroid-cream history (open question — many patients do not volunteer this).
- Current medications and supplements.
- Family history of severe acne, scarring, hirsutism, or PCOS.
- Smoking, alcohol, and gym/anabolic-supplement context.
- Pregnancy plans within the next 6–12 months.
GAGS (Global Acne Grading System) — applied to cystic disease
The GAGS score weights each lesion type by severity (comedones × 1, papules × 2, pustules × 3, nodules × 4) and multiplies by a factor for each anatomical zone (forehead × 2, each cheek × 2, nose × 1, chin × 1, chest and upper back × 3). Scores classify acne as mild (1–18), moderate (19–30), severe (31–38), or very severe (39+). Cystic acne lesions, as nodules, drive the score upwards quickly. A patient with even a modest count of nodulocystic lesions on the cheeks and chin will sit in the severe band.
Mild — GAGS 1–18
Mostly comedones with a few papules. Cystic lesions absent or rare. Standard topical pathway is appropriate first-line.
Moderate — GAGS 19–30
Mixed inflammatory acne with occasional nodules. Topical combination therapy ± short course oral antibiotic plus retinoid. Hormonal evaluation if adult female.
Severe / very severe — GAGS 31+
Multiple nodules, cysts, sinus tracts, or active scarring. Isotretinoin candidacy formally evaluated. Hormonal pathway considered in parallel for adult women.
Investigations that may be ordered
Investigations are not required in every cystic acne consultation, but specific situations call for them. Adult female patients with a hormonal pattern may need a free testosterone, DHEA-S, fasting insulin, and a pelvic ultrasound to evaluate PCOS. Patients being assessed for isotretinoin need baseline complete blood count, liver function tests, fasting lipids, and a serum pregnancy test in women of reproductive age. Patients with sudden severe cystic acne accompanied by systemic symptoms may need inflammatory markers, joint imaging, and same-day dermatology contact. Investigations are tailored — they are not a routine package upsold to every patient.
The cystic acne treatment ladder
Severe cystic disease is treated as severe from the start — escalation is faster than for ordinary acne, and the focus is on stopping further scar accumulation. The ladder below shows the framework; the actual plan is built in the consultation against your GAGS score, scar status, and prior history. Cross-reference with the broader parent acne treatment ladder for context on the milder grades.
Selected patients with isolated cystic lesions on a background of moderate inflammatory acne. Topical retinoid (adapalene 0.1–0.3% or tretinoin 0.025–0.05%) nightly, benzoyl peroxide 2.5–5% wash, and a short course oral antibiotic (doxycycline 100 mg daily for 8–12 weeks) paired with the topicals. Reviewed at 6 weeks and 12 weeks.
Reduction in inflammatory load by ≥ 50 %, halt of new cyst formation, no new scars on serial photographs. If targets are not met, escalation to S2 is appropriate rather than another antibiotic course.
Topical retinoid continued long-term. Antibiotic stopped at end of course; never re-prescribed reflexively. PIH care initiated once active acne stable.
Multiple nodules, occasional cysts, no sinus tracts, scarring not yet aggressive. Oral isotretinoin candidacy formally evaluated. If isotretinoin is deferred — by patient choice, planned pregnancy, or contraindication — combined therapy with oral antibiotic (doxycycline or lymecycline) plus topical retinoid plus benzoyl peroxide, with hormonal evaluation in adult women, runs in parallel with monthly review.
Sustained clearance, no new scars on serial photographs, reduction of nodular load by 75 %+, preparation for post-active-disease maintenance.
Topical retinoid maintenance long-term. Three-monthly reviews in the first year. Hormonal management continued if indicated.
Widespread nodulocystic disease, sinus tracts, real-time scar formation, prior failed antibiotic courses. Isotretinoin is the most evidence-supported option in this band, after full assessment, baseline investigations, and contraception counselling. Initial dose typically 0.5 mg/kg/day, titrated against tolerability and response towards a cumulative target dose in the 120–150 mg/kg range over the course. Monthly review of dryness, mood, lipids, and liver function. Adult women may also be evaluated for hormonal therapy.
Halt of scar formation. Sustained clearance of inflammatory and cystic lesions. Cumulative dose adequate to support durable remission. PIH and existing-scar pathways planned for 3–6 months after isotretinoin completion.
Post-isotretinoin relapse monitoring for 12 months. Topical retinoid at low frequency long-term. Hormonal maintenance if indicated. Scar treatment planned only after stable interval.
Sudden severe ulcerative cystic acne with systemic symptoms (fulminans), or disease refractory to a complete isotretinoin course. Initial systemic corticosteroids to control acute inflammation, often with overlap into low-dose isotretinoin. Co-management with rheumatology if SAPHO-spectrum features. Specialist dermatology, frequently inpatient.
Acute control of systemic inflammation, prevention of disfiguring scarring, transition to maintenance. Outcomes are individualised; this band is uncommon and managed case-by-case.
Long-term dermatology follow-up, multidisciplinary input as needed.
Hormonal pathway in adult female cystic acne
Who qualifies
Adult women with cystic disease distributed on the lower face, chin, and jawline; cyclic flares before menstruation; confirmed or suspected PCOS; raised free testosterone or DHEA-S; failure of standard topical-and-antibiotic regimens despite adherence.
Treatment options
Combined oral contraceptive pills with anti-androgenic progestins, or spironolactone (off-label but evidence-supported), prescribed by the dermatologist or in coordination with a gynaecologist. Hormonal therapy is rarely a sole intervention in cystic disease — it is usually combined with a topical regimen and may be combined with isotretinoin in carefully selected cases.
Antibiotic stewardship
Oral antibiotics in cystic acne are kept short (8–12 weeks maximum), always paired with benzoyl peroxide and a retinoid, never repeated reflexively, and never used as long-term monotherapy. Repeated antibiotic exposure breeds resistance and reduces future options. Patients on multiple prior courses are usually candidates for systemic therapy that addresses the driver, not another antibiotic.
What we explicitly do not do
- We do not prescribe long, repeated oral antibiotic courses without escalation. Antibiotic monotherapy beyond 12 weeks is not appropriate in cystic disease.
- We do not start aggressive lasers or peels during an active cystic flare. The PIH and rebound-flare risk in Indian skin is too high.
- We do not promise a permanent end-state. Maintenance after clearance is the realistic and honest plan; recurrence is biology, not failure.
- We do not sell fixed all-inclusive packages. Cystic acne treatment is graded and individualised; package pricing distorts the clinical decision.
- We do not start treatment without baseline clinical photographs. Photographs are the only objective record of progress in cystic acne.
Isotretinoin for cystic acne — candidacy, dosing, monitoring
Oral isotretinoin (13-cis-retinoic acid) is the most extensively evidenced treatment for severe nodulocystic acne. It is the only modality that addresses sebum production, follicular plugging, C. acnes, and inflammation simultaneously, and it is the only treatment that can produce durable remission in a high proportion of patients with severe disease. It is also a regulated medication with a precise prescribing protocol. The detail below is the working framework used at DDC; the actual decision sits in the consultation.
Who is a candidate
- GAGS in the severe or very-severe band (31+), particularly with multiple nodules or cysts.
- Active scar formation on serial photographs, regardless of GAGS — scarring is itself an indication.
- Failure of an adherent combination regimen (topical retinoid + benzoyl peroxide + an appropriate oral antibiotic) at 12–16 weeks.
- Persistent disease into adulthood with significant psychosocial impact and prior failed standard treatments.
- Sinus tracts or recurrent nodulocystic lesions in the same area, which generally do not respond to topical-only regimens.
- Patient willing and able to comply with monitoring — monthly review, periodic blood tests, and the contraception protocol where relevant.
Who is not a candidate (or where deferral is needed)
- Pregnancy is an absolute contraindication. Isotretinoin is a category-X teratogen — it causes severe and characteristic birth defects. Women of reproductive age must use the agreed contraception protocol throughout treatment and for at least one month after stopping.
- Active suicidality or untreated severe depression. Mood effects on isotretinoin are uncommon but real; the medication is not started in the presence of unstable mental health without psychiatric input.
- Significant uncontrolled liver disease or marked baseline hyperlipidaemia — both warrant control before initiation.
- Concurrent tetracycline use — increases risk of pseudotumor cerebri and is contraindicated.
- Vitamin A toxicity history or recent high-dose vitamin A supplementation.
- Active allergy to formulation components, recognised peanut/soy allergy with relevant capsule excipients in some brands.
Baseline workup before starting
Investigations
- Complete blood count.
- Fasting lipid profile (total cholesterol, LDL, HDL, triglycerides).
- Liver function tests (ALT, AST, alkaline phosphatase, bilirubin).
- Serum pregnancy test in women of reproductive age (β-hCG).
- Selected patients: thyroid panel, free testosterone, DHEA-S, fasting insulin (women with PCOS pattern).
Counselling
- Teratogenicity warning and signed consent.
- Contraception protocol — two reliable methods for women of reproductive age, throughout treatment and for one month after.
- Side-effect briefing: dryness, lip and nasal mucosa, dermatitis, photosensitivity, transient flare in early weeks, mood awareness, joint and muscle aches.
- Drug interaction review — tetracyclines avoided, certain other retinoids avoided, alcohol moderation.
- Realistic timeline: 4–6 months active treatment in most cases; some patients require longer or a second course.
Dosing framework
The traditional framework targets a cumulative dose of approximately 120–150 mg/kg over the course, divided across daily dosing. Initial dose is typically 0.5 mg/kg/day for the first month, titrated upwards to 0.5–1.0 mg/kg/day based on tolerability and response. Lower-dose regimens (0.25–0.4 mg/kg/day for longer durations) may be used in selected patients, particularly adult women with predominantly hormonal patterns, with the understanding that cumulative dose still drives durable-remission probability. The exact dose is a clinical decision against weight, GAGS, prior history, and tolerability — there is no fixed protocol that applies to every patient.
Monthly monitoring
- Clinical review at 4-week intervals during active treatment.
- Repeat lipid panel and liver function at 4–6 weeks, then periodically (typically every 8–12 weeks) thereafter.
- Pregnancy test repeated monthly in women of reproductive age throughout treatment.
- Mood and joint review at every visit.
- Photograph-led response tracking — photographs at baseline, month 1, month 3, and end of course.
- Dryness management plan adjusted at each visit (lip balm cadence, moisturiser, eye lubrication, sunscreen, occasional intranasal saline).
After the course — relapse and re-treatment
Many patients remain clear for years after a complete cumulative-dose isotretinoin course. The realistic figure quoted in the literature is that roughly 20–30 % of patients have at least one relapse needing some form of further treatment, and a smaller subset eventually need a second isotretinoin course. Relapse is more common when the cumulative dose is below the standard target range, when the patient is very young at the first course, or when hormonal drivers persist. Re-treatment is reasonable, evidence-supported, and follows the same protocol with fresh baseline workup. Recurrence is biology, not failure of the original treatment.
What happens at the clinic — including intralesional injection
Cystic acne treatment is mostly medical — tablets, topicals, blood tests, photographs, monthly reviews. The two procedural elements that come up most often are intralesional triamcinolone for an acute painful cyst, and sequenced post-acne procedures (peels, microneedling, laser) timed only after active disease is stable. Both are described here in plain language.
Intralesional triamcinolone — what it is, when it is used
What it is
A very small injection of dilute triamcinolone acetonide — typically 2.5 mg/mL, occasionally 5 mg/mL — directly into the centre of a single inflamed cyst. The volume is small (often 0.05–0.1 mL per lesion). The needle is fine-gauge, the procedure takes seconds, and the pain is similar to a mild pinprick.
The cyst usually flattens within 24–72 hours. The mechanism is local anti-inflammatory action — the steroid suppresses the inflammatory cascade in the deep dermis around the lesion, the cyst loses pressure, and the surrounding skin settles.
When it is used
- A single large painful cyst before a wedding, exam, surgery, or family event.
- An acute flare lesion that is causing significant pain or sleep disruption.
- A cyst that is at high risk of leaving a depressed scar if it ruptures into the dermis untreated.
- Not used for diffuse acne. It is an adjunct for individual lesions, not a routine treatment for the field.
Risks of intralesional triamcinolone
- Local atrophy — a small depressed mark at the injection site, more common with higher concentration, repeated injection of the same lesion, or superficial injection. Usually settles over weeks to months but occasionally persists.
- Local hypopigmentation — a paler patch at the injection site, more common in Fitzpatrick III–V skin, often slow to recover and occasionally permanent in a small minority.
- Local telangiectasia — fine visible vessels at the site, uncommon, usually settles.
- Systemic effects — rare with the very small doses used, but theoretically possible with repeated multi-site injection in the same session.
- Risk-benefit framing — for one acute painful cyst before an event, the alternative of leaving it to scar untreated usually outweighs the small local risk. For routine acne, the calculation is different and intralesional injection is not appropriate.
Visit pattern through a course
Full history, examination, GAGS scoring, baseline photographs, written plan. If isotretinoin is being considered: investigations ordered, contraception counselling, consent form provided. Topical regimen often started even in patients who will later move to isotretinoin, to begin barrier preparation.
Review of investigations, photograph comparison, side-effect check, topical adjustment. If isotretinoin: prescription initiated at the appropriate starting dose, dryness management plan reviewed, monthly follow-up scheduled.
Clinical review, photograph comparison, repeat blood work where indicated, pregnancy test in women of reproductive age, dose adjustment, side-effect management. Scar formation explicitly tracked.
Cumulative-dose review, photograph comparison against baseline, discussion of maintenance, planning for any post-acne PIH and scar pathways. End-of-treatment investigations as indicated.
Relapse monitoring. Topical retinoid maintenance review. Initiation of post-acne PIH and scar pathways now that the field is stable.
Who is a good candidate for the cystic acne pathway
Suitability is graded against severity, prior history, current health, and reproductive plans. The matrix below is a framework — consultation confirms what applies to you.
Why cystic acne treatment in Indian skin is calibrated differently
Indian skin (Fitzpatrick III–V) responds to inflammation with more intense and longer-lasting pigmentation than lighter skin types. A cystic lesion that resolves with a small pink mark in Fitzpatrick I–II skin frequently leaves a deep brown-grey patch in Fitzpatrick IV–V skin that takes months to fade. This is biology — melanocytes in pigmented skin respond more vigorously to inflammatory cytokines.
Two consequences flow from this. First, every additional inflammatory episode adds pigment debt that takes longer to clear than the lesion itself. Untreated cystic acne therefore generates two visible problems for the price of one. Second, aggressive procedural intervention during active disease — a strong peel, an ablative laser, an unsuitable microneedling protocol — risks both new PIH and a rebound flare. The PIH from a misjudged peel can outlast the cyst it was trying to address.
The DDC approach calibrates against this from the first visit. Topical retinoids are introduced at the lower concentration, gradually titrated upwards. Benzoyl peroxide is paired with a barrier-supportive moisturiser to reduce irritation. Sunscreen is non-negotiable — daily, broad-spectrum, oil-free, SPF 30 or higher, year-round. Procedures are sequenced after active disease is stable, never simultaneously. Photographs are reviewed under standardised lighting because PIH and erythema look different under bathroom and clinic light.
Photoprotection is doing more work than patients realise. Sun exposure worsens PIH, accelerates retinoid irritation, and reduces the predictability of any laser or peel that comes later. Skipping sunscreen during cystic acne treatment is the single most common reason patients are unhappy with their post-treatment skin tone. The dermatologist will repeat this at every visit because it matters that much.
What Indian-skin calibration changes
- Topical retinoid concentration starts lower and is titrated up.
- Peels are gentler — mandelic and lactic preferred over high-strength glycolic during active disease.
- Laser settings, where used at all, are conservative; ablative resurfacing is deferred until acne is stable.
- Sunscreen is daily, year-round, including indoor and overcast days.
- Photographs are reviewed under standardised lighting.
- Hyperpigmentation pathway is initiated only after active acne is stable — not in parallel.
What patients can do daily
- Apply broad-spectrum SPF 30+ each morning, indoors and out.
- Reapply if outdoors for prolonged periods or sweating heavily.
- Use a gentle non-foaming or low-foaming cleanser; no scrubs.
- Keep the moisturiser non-comedogenic and oil-free; use it consistently.
- Never pick, squeeze, or extract cystic lesions.
- Photograph the same areas in the same lighting every two weeks.
Why cystic acne is treated as urgent dermatology
Every untreated cyst carries scar risk. The accelerated escalation logic on this page is designed around scar prevention as the central clinical objective, not just lesion clearance. Once scars form, they are addressed on a separate procedural pathway — and they do not simply fade with time the way pigment marks do.
The biology is uncomfortable to read but worth being honest about. A cyst that ruptures deep in the dermis releases inflammatory contents into surrounding tissue. Neutrophil enzymes and bacterial products damage the collagen architecture faster than fibroblasts can repair it. The skin reseals — but it reseals with disorganised collagen, depressed contour, or thickened scar tissue. The scar is permanent without dermatological intervention. No skincare product, no facial, no diet change, no time, will return the dermis to its original architecture once scarring has occurred.
This is why cystic acne escalation is faster than ordinary acne escalation. If a topical-and-antibiotic regimen for severe disease shows no meaningful response at 4–6 weeks, or if scars are already forming on photographs, the right next step is dermatologist review — not another six-month antibiotic trial. Waiting "to see how it settles on its own" is the most common reason patients arrive with a face full of scars asking for procedural correction.
The accelerated escalation logic at DDC is specifically: a documented cystic flare with scar formation triggers isotretinoin candidacy evaluation at the next visit, not after another full antibiotic course. The threshold for moving to systemic therapy is lower in this band because the cost of waiting is permanent.
Real-time scar formation
New ice-pick, boxcar, or rolling scars visible on photographs from one month to the next. Direct indication for systemic therapy regardless of GAGS. Topical-only continuation in this pattern is below the standard of care.
Sinus tracts under the skin
Connected channels between adjacent cysts. Almost always require systemic therapy. Continued topical-only management has poor evidence.
Repeated cysts in the same area
Several cysts in the same anatomical zone over months suggest deeper follicular involvement than ordinary acne. Indication to escalate the plan rather than repeat antibiotics.
What scar prevention actually requires from the patient
- Do not pick, squeeze, or extract cystic lesions. Manual manipulation drives inflammation deeper and is the single most preventable cause of scar formation.
- Photograph the same areas every two weeks under the same lighting. Scar formation is most reliably detected on serial photographs, not in mirrors.
- Attend monthly reviews on schedule. The escalation logic depends on the dermatologist seeing what is happening between visits.
- Take prescribed medication consistently for the full course. Stopping early because skin "looks better" is a leading cause of relapse and re-scarring.
- Sun protection daily. Sun exposure stiffens the inflammatory environment and worsens both PIH and scar formation.
- Raise scarring concerns explicitly at any visit. If you can see new depressions or raised areas in the affected skin, say so — the response is to escalate, not reassure.
What realistic results look like — and when
Cystic acne does not clear in weeks. Honest timelines are part of the plan. The figures below are evidence-based ranges that apply to most patients on adherent treatment; individual response varies and is reviewed at every visit.
Topical regimen introduced or escalated, oral medication started where appropriate. Skin can feel drier, slightly more red, occasionally more irritated. New lesions may still appear because lesions already in formation will continue to surface. Pain on existing cysts may settle within days; visible flattening takes longer. Photographs at week 4 establish the working baseline.
First measurable reduction in inflammatory load. Most patients on isotretinoin show clear photographic improvement by week 8–12; topical-only patients with severe disease may show less, which is itself the trigger for escalation. Initial flare on isotretinoin (10–20 % of patients) settles in this window. PIH from older lesions becomes more visible as active inflammation reduces, which is normal and is addressed on the PIH pathway later.
Sustained reduction in nodular and cystic load. Halt of new scar formation. Sustained reduction in pain. End of active treatment cycle for most isotretinoin courses; cumulative dose reviewed against target. Topical maintenance plan finalised. Initial discussion of post-acne PIH and scar pathways.
Topical retinoid 2–3 nights weekly long-term. Three-monthly reviews in the first year. Hormonal management continued where indicated. PIH pathway initiated. Scar treatment pathways planned only after a stable interval — typically 3–6 months after isotretinoin completion.
Annual or six-monthly reviews. Relapse, where it occurs, is recognised early and addressed before scar reaccumulation. A second isotretinoin course in selected cases is reasonable and follows the same protocol.
Outcomes are evidence-based ranges, not promises. Recurrence is part of the biology of severe acne and is addressed within the maintenance plan. No single timeline applies to every patient.
Side effects, monitoring, and how risks are managed
Severe-acne medications have recognised side-effect profiles. They are not hidden; they are explained at consent, monitored at every review, and managed actively when they arise. The list below is the working framework — your specific risks are reviewed in the consultation.
Isotretinoin — common, expected effects
- Lip dryness — universal; lip balm cadence advised.
- Facial dryness and dermatitis — managed with non-comedogenic moisturiser.
- Dry eyes — artificial-tear drops as needed.
- Dry nasal mucosa — saline spray; minor nosebleeds are common.
- Photosensitivity — daily SPF 30+ non-negotiable.
- Joint and muscle aches at higher doses — usually mild.
- Initial flare in weeks 2–6 — managed with dose adjustment and, in severe early flares, short oral corticosteroids overlapping initiation.
- Transient lipid and liver enzyme rise — monitored on schedule, dose adjusted if needed.
Isotretinoin — rare, important effects
- Teratogenicity — absolute contraindication in pregnancy; the contraception protocol is mandatory and signed.
- Mood effects — uncommon but reported; reviewed at every visit; psychiatric input ahead of initiation if relevant history.
- Inflammatory bowel disease association — debated in the literature; gastroenterology input where relevant history.
- Pseudotumor cerebri — very rare; tetracycline co-prescription specifically avoided to reduce risk.
- Severe hyperlipidaemia or transaminitis — uncommon; addressed by dose reduction or withdrawal as indicated.
- Nyctalopia (reduced night vision) — uncommon; relevant for occupations requiring night driving.
Oral antibiotics — what to know
- Doxycycline and lymecycline are first-line oral antibiotics in cystic disease where used. Course length is capped at 8–12 weeks and always paired with benzoyl peroxide and a topical retinoid.
- Photosensitivity is a recognised effect; daily SPF 30+ is essential during the course.
- Gastrointestinal side effects (nausea, oesophageal irritation) — take with water, sit upright for 30 minutes after taking, avoid taking just before bed.
- Do not use simultaneously with isotretinoin (pseudotumor cerebri risk).
- Repeated long courses breed bacterial resistance and reduce future options. Antibiotic stewardship is enforced.
Intralesional triamcinolone — risks recap
- Local atrophy at the injection site — small depressed mark; usually settles, occasionally persists.
- Local hypopigmentation — paler patch; more common in Fitzpatrick III–V.
- Local telangiectasia — fine vessels; uncommon.
- Rarely systemic effects with very small doses; theoretically possible with multi-site injection in one session.
What cystic acne treatment costs — and why no fixed packages
Cystic acne treatment is graded and individualised. A single tender cyst before a wedding and a widespread nodulocystic flare are very different clinical situations. Fixed all-inclusive packages distort that decision, so we do not offer them. What we offer is transparent costing, in writing, before treatment begins.
Consultation
Full dermatologist consultation, GAGS scoring, written plan, baseline photographs, costed onward pathway. Consultation fee applies whether or not treatment proceeds.
Topical-and-antibiotic plan
Costed against the specific products and review schedule. Generally lower-cost than a full procedural pathway. Indicative range provided in writing at the consultation.
Isotretinoin course
Costed against drug supply, monthly reviews, and serial blood work. Indicative range over a typical 4–6 month course is provided at the consultation. No fixed package; no upselling.
* Starting price covers consultation only. Onward treatment costs depend on regimen, supply, investigations, and review frequency. Indicative ranges are provided in writing at the first visit.
What you are paying for
- Dermatologist time — full assessment, written plan, monthly review, photograph-led tracking.
- Investigations where needed — baseline blood work, periodic monitoring, hormonal workup in selected cases.
- Medication supply — topical and oral, sourced from regulated suppliers.
- Procedural adjuncts where indicated — intralesional triamcinolone for an acute lesion is a small added charge per lesion treated.
- No charge for photograph review at scheduled visits. Photographs are clinical records, not a billable extra.
How treatment options compare for cystic acne
A consolidated reference. The right choice depends on grade, prior history, scar status, and reproductive plans — not on the table alone. Use this against the more comprehensive ladder on the parent acne hub if you are managing milder grades.
| Option | Where it fits | What it does well | What it does not address | Time to judge | PIH / safety risk |
|---|---|---|---|---|---|
| Topical retinoid + BPO | Mild cystic background, maintenance | Comedonal control, prevents new lesions, supports antibiotic stewardship | Established nodulocystic load, hormonal drivers | 8–12 weeks | Low if titrated |
| Oral antibiotic + topicals | Moderate cystic, short courses (8–12 weeks) | Systemic anti-inflammatory effect, halt of progression in many cases | Long-term clearance (must move on after course) | 4–8 weeks | Low; stewardship enforced |
| Hormonal therapy | Adult female with hormonal pattern | Addresses androgen-driven sebum, useful in PCOS | Bacterial drivers; severe cysts alone | 3–6 months | Cardiovascular review needed |
| Oral isotretinoin | Severe nodulocystic, refractory, scarring | Targets all four acne drivers; durable remission in a high proportion | Pregnancy contraindication; needs monitoring | 4–6 months active | Defined, monitored profile |
| Intralesional triamcinolone | Single acute painful cyst | Flattens within 24–72 hours; reduces scar risk on that lesion | Field disease — adjunct only, not a standalone regimen | 1–3 days | Local atrophy / pigment risk if mis-dosed |
| Salicylic / mandelic peel | Comedonal adjunct once acne is stable | Penetrates oil-rich follicles; gentler in Indian skin | Severe nodulocystic, scarring | Series of 4–6 sessions | Moderate if mistimed in active disease |
| Laser / IPL | Post-active-disease PIH and erythema | Targets pigment / capillaries once acne stable | Active inflammation, hormonal cause | Series of 3–6 sessions | Higher in Indian skin; conservative settings |
What "before and after" honestly looks like in cystic acne
Before-and-after photographs in cystic acne are clinical records, not marketing. They are taken in standardised lighting, reviewed at each visit, and used to drive treatment decisions. The expectations below describe what realistic clinical photographs typically show.
What improves first
- Pain on existing cysts within days (especially after intralesional injection).
- Active inflammation and redness at 4–8 weeks.
- Cyst count and frequency at 8–12 weeks.
- Scar-formation rate halts on serial photographs as inflammation reduces.
What takes longer
- Post-inflammatory hyperpigmentation — months, not weeks; addressed on the PIH pathway after acne is stable.
- Existing depressed and raised scars — do not fade with time; addressed on procedural pathways once acne is stable.
- Skin texture and pore size — gradual change over 6–12 months on maintenance.
- Confidence — patients almost always report subjective improvement lagging objective photographic improvement by weeks.
If this is your situation, then this is the framework — and why
A short decision matrix patients find useful when reading the page for the first time. The "because" line explains the clinical reasoning, so the framework is portable rather than a list of recommendations to memorise.
Daily routine that supports — but does not replace — medical treatment
Skincare alone does not control cystic acne. But a calibrated daily routine reduces irritation, supports the medical regimen, and makes the difference between a patient who tolerates treatment well and one who has to pause it. The list below is the working framework; specifics are tailored at the consultation.
Morning
- Gentle non-foaming cleanser; lukewarm water; pat dry, do not rub.
- Non-comedogenic, oil-free moisturiser if topicals are causing dryness.
- Broad-spectrum SPF 30+ daily, indoors or out, every morning.
- Topical antibiotic + BPO combination if prescribed — applied thinly to affected zones.
Evening
- Gentle cleanser; remove sunscreen, makeup, and the day's pollution load.
- Topical retinoid (adapalene or tretinoin) applied as prescribed — pea-size for the whole face, not per lesion.
- Non-comedogenic moisturiser layered over the retinoid if dryness is a problem (skip-night strategy is acceptable in early weeks).
- No additional actives (vitamin C, glycolic acid, exfoliants) unless approved by the dermatologist; layering risks barrier collapse.
Practical do's and don'ts
- Photograph the same areas every two weeks under similar lighting.
- Change your pillowcase twice a week.
- Shower soon after sweating; change gym clothes promptly.
- Use lip balm consistently if on isotretinoin.
- Carry artificial tears if your eyes feel dry on isotretinoin.
- Pick, squeeze, or extract cystic lesions.
- Use topical steroid creams on the face without medical supervision.
- Layer multiple actives (acids, vitamin C, retinoid) on broken or inflamed skin.
- Visit beauty salons for "deep cleaning" facials during active disease.
- Sun-tan, even briefly, while on isotretinoin or doxycycline.
How Delhi's environment changes the cystic acne plan
Delhi has four distinct environmental phases that affect cystic acne. Summer brings peak heat, humidity in the build-up to the monsoon, sweat-driven follicular load, and increased oil production. Monsoon brings wet humidity, fungal overlap on the upper trunk, and the temptation to over-cleanse. Winter brings low humidity, barrier dryness, and over-application of heavy moisturisers that can be comedogenic. Autumn brings the worst pollution episodes — particulate matter that adds oxidative stress to skin already inflamed.
The treatment plan adjusts subtly across these phases. In summer and monsoon the topical retinoid concentration may be held steady or slightly reduced if irritation peaks; sunscreen reapplication frequency rises. In winter the moisturiser becomes the make-or-break product; a non-comedogenic, fragrance-free, ceramide-supportive formulation is preferred over heavy occlusive creams. In autumn pollution episodes, evening cleansing is stricter and antioxidant skincare may be added if the dermatologist agrees it suits the regimen.
None of these adjustments substitutes for the medical regimen. They shape tolerability rather than efficacy. But tolerability is what determines whether the treatment can be continued on schedule, which is what determines outcome.
Seasonal calibration
- Summer (April–June): SPF reapplication every 2–3 hours outdoors; lighter moisturiser; retinoid frequency held steady or slightly down if irritation peaks.
- Monsoon (July–September): watch for fungal overlap on chest and back (Pityrosporum folliculitis); avoid over-cleansing.
- Autumn (October–November): stricter evening cleansing during severe pollution; antioxidant skincare considered.
- Winter (December–February): moisturiser becomes the central product; heavy occlusive creams avoided in favour of lighter, ceramide-supportive formulations.
What does not change
- Daily SPF 30+, year-round, indoors and out.
- The medical regimen unless the dermatologist adjusts it explicitly.
- The do-not-pick rule.
- Photograph-led monthly review.
Cystic acne — common myths and reassurances
Cystic acne is one of the most myth-laden conditions in dermatology and the myths cost patients real time. Wrong beliefs delay escalation, lead to harmful self-treatment, and shape unrealistic expectations on either side. Each myth below is paired with the evidence-based reality and a single practical reassurance.
Myth: cystic acne is just severe ordinary acne
Reality: Cystic acne involves deeper dermal inflammation than ordinary acne, with sinus tracts and consistent scar risk. The treatment threshold and escalation logic are different. Treating it as if it were ordinary moderate acne is the most common reason patients arrive with avoidable scars.
Practical reassurance: recognising it as severe is itself protective; it changes what gets escalated and when.
Myth: isotretinoin permanently damages the liver
Reality: Transient mild rises in liver enzymes during isotretinoin are common and reversible; significant transaminitis is uncommon and reversible on dose reduction or withdrawal. Permanent liver damage attributable to a properly monitored isotretinoin course is not an established outcome in the literature.
Practical reassurance: the standard monitoring schedule catches the small minority of patients who need a dose change.
Myth: isotretinoin causes depression in everyone who takes it
Reality: Mood effects on isotretinoin are uncommon. Most published cohort and case-control data do not show a population-level increase in depression incidence; severe acne itself is associated with depressive symptoms, and clearance frequently improves mood scores. Patients with relevant psychiatric history are reviewed before initiation.
Practical reassurance: the medication is started with mood baseline noted and reviewed at every visit.
Myth: drinking water and skincare alone will clear it
Reality: Hydration and skincare are supportive — they do not reverse the dermal inflammatory cascade in cystic disease. Cystic lesions are not hydration deficits; they are deep inflammatory events that require medical treatment to control. Skincare alone in established cystic disease is the slow path to scarring.
Practical reassurance: the daily routine matters; it just is not, on its own, the treatment.
Myth: facials and "deep cleaning" extractions help cysts
Reality: Salon extractions on cystic lesions push inflammation deeper, increase the rupture surface, and frequently leave a worse mark or scar than leaving the cyst alone. They are explicitly contraindicated during active disease. A cyst is not a comedone and cannot be safely extracted from the surface.
Practical reassurance: for one acute painful cyst, the right answer is intralesional triamcinolone, not extraction.
Myth: once it clears, you can stop everything
Reality: The most common reason for relapse in severe acne is discontinuing maintenance immediately after clearance. Topical retinoid maintenance several nights a week is the realistic plan after a successful course. Stopping completely because the skin "looks better" is the leading driver of patients arriving for a second isotretinoin course they could have avoided.
Practical reassurance: maintenance is light, low-frequency, and well-tolerated by most patients.
Myth: lasers and peels are the modern alternative to isotretinoin
Reality: Lasers and peels are adjuncts for stable post-acne skin — pigment, erythema, scar architecture — once active disease is controlled. They are not substitutes for systemic therapy in active cystic disease, and using them on active inflammation in Indian skin worsens both the inflammation and the post-inflammatory hyperpigmentation.
Practical reassurance: the procedures are still available — just sequenced after acne is stable, where they actually work safely.
Myth: it always comes back, so why bother
Reality: Many patients remain clear for years after a complete cumulative-dose isotretinoin course; relapse rates are quoted around 20–30 % across published series, with re-treatment available. The framing "always comes back" is not what the evidence shows. Even in patients who do relapse, scar prevention during the active phase is permanent benefit.
Practical reassurance: scar prevention is not undone by relapse; the structural skin saved during active treatment stays saved.
What this page does not replace
The detail above is medical education for patients and is written to be useful before a visit. It is not personal medical advice, it is not a treatment recommendation, and it does not substitute for a consultation. Three boundaries are worth restating directly.
- It does not replace a consultation. Cystic acne treatment is graded against your specific GAGS score, scar status, prior history, reproductive plans, and current health — none of which can be determined from a webpage. Treatment is started after assessment, not after reading.
- It does not constitute a prescription. The drug names, doses, and protocols described here are written so patients understand the framework. The prescription itself is a clinical decision made for you, in writing, after the consultation.
- It does not promise outcomes. Outcomes on this page are evidence-based ranges drawn from published literature. They describe what most patients on adherent treatment can expect; they do not promise what will happen in your case. Recurrence is part of severe-acne biology, not a failure of treatment.
Terms used on this page
Plain-language definitions for the clinical terms used throughout. The list is not exhaustive — your dermatologist will define any unfamiliar terms specific to your plan during the consultation.
Nodulocystic acne
The medical name for cystic acne. Refers to the deepest inflammatory pattern of acne, with nodules (firm tender lumps) and cysts (fluid-filled lesions) involving the deep dermis.
GAGS (Global Acne Grading System)
A weighted scoring system that combines lesion type and anatomical zone to classify acne as mild, moderate, severe, or very severe. Used to choose treatment intensity and to track response objectively.
Isotretinoin
13-cis-retinoic acid. The most extensively evidenced systemic treatment for severe nodulocystic acne. Targets sebum, follicular plugging, C. acnes, and inflammation simultaneously. Absolutely contraindicated in pregnancy.
Intralesional triamcinolone
A small injection of dilute steroid (typically 2.5 mg/mL) directly into a single inflamed cyst. Flattens the lesion within 24–72 hours. Used as an adjunct for individual lesions, not as a routine acne treatment.
Cumulative dose
The total dose of isotretinoin received across the entire course, expressed in mg/kg of body weight. Cumulative dose in the 120–150 mg/kg range is the traditional target associated with durable remission probability.
Post-inflammatory hyperpigmentation (PIH)
Flat dark or greyish marks left by inflammation. Not a scar; a pigment change. More common, larger, and slower to fade in Indian skin (Fitzpatrick III–V) than in lighter skin types.
Sinus tracts
Connected channels between adjacent cysts under the skin. A feature of severe nodulocystic disease and an indication for systemic therapy in most cases.
Acne fulminans
Sudden severe ulcerative cystic acne with systemic symptoms (fever, joint pain, malaise). A medical emergency requiring urgent dermatology and frequently inpatient management with systemic corticosteroids before isotretinoin.
Who reviews and writes this page
This page is reviewed against current dermatology guidance by Dr Chetna Ghura, the lead dermatologist at Delhi Derma Clinic. Last reviewed April 2026; next review due April 2027. The named reviewer signs off the published version against the served URL and the commit hash on which the content was last edited.
Dr Chetna Ghura
MBBS, MD Dermatology
DMC 2851 · 16 years of dermatology practice
Lead dermatologist at DDC. Indian-skin specialist with a working caseload across cystic acne, hormonal acne in adult women, post-inflammatory hyperpigmentation, and acne-scar pathways. Reviews and signs off this page against the published URL and current commit hash.
Related reading at DDC
Acne Treatment (parent hub)
The umbrella page covering all acne grades, including the milder bands not detailed here.
Hormonal Acne Treatment
Adult female acne, PCOS overlap, and the hormonal pathway as a sibling sub-treatment page.
Adult Acne Treatment
The adult-onset and persistent-adult acne pattern, with the specific drivers and treatment differences.
If you are searching for an entry point to the broader skin and acne content, the parent acne hub is the canonical starting page.
Honest answers before you book
Sixteen questions covering the patterns, process, safety, Indian-skin considerations, clinical detail, cost, prior-failure handling, and maintenance specific to cystic acne. Every answer is written to stand alone in search results and AI-overview extraction.
What is the difference between cystic acne and ordinary acne?
Why do cysts hurt when ordinary pimples do not?
Does cystic acne always scar?
Can cystic acne return after isotretinoin?
How quickly should cystic acne be treated?
What is intralesional triamcinolone injection?
Will my dermatologist start with topicals before isotretinoin?
Is isotretinoin safe for cystic acne in Indian patients?
Can intralesional steroids cause skin thinning?
Why do cysts leave such dark marks on Indian skin?
Is laser safe to use on Indian skin during active cystic acne?
What is GAGS grading and how does it apply to cystic acne?
What blood tests are needed before isotretinoin?
What does cystic acne treatment cost in Delhi?
I have already tried antibiotics multiple times — what now?
What does maintenance after isotretinoin look like?
Public reference layer
This page draws on internationally recognised dermatology references for educational accuracy. It does not reproduce clinical guidelines verbatim and does not constitute personal medical advice. The named reviewer signs off the published version against the served URL and the current commit hash.
- 1Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2016;74(5):945–973.
- 2Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews. 2018, Issue 11. Art. No.: CD009435.
- 3Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris — 10 years later: a safe and successful treatment. British Journal of Dermatology. 1993;129(3):292–296.
- 4Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. International Journal of Dermatology. 1997;36(6):416–418. (GAGS reference)
- 5Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Archives of Dermatology. 1983;119(6):480–481. (Intralesional triamcinolone reference)
- 6Nast A, Dréno B, Bettoli V, et al. European evidence-based guidelines for the treatment of acne. Journal of the European Academy of Dermatology and Venereology. 2012;26(S1):1–29.
- 7American Academy of Dermatology — Acne patient education and clinical resources. Available at: aad.org/public/diseases/acne
- 8Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infectious Diseases. 2016;16(3):e23–e33.
- 9Karadag AS, Aslan Kayıran M, Wu CY, Chen W, Parish LC. Toxic effects of isotretinoin on skin and mucosa: monitoring and managing dryness. Dermatologic Therapy. 2020;33(4):e13577.
- 10Layton A. The use of isotretinoin in acne. Dermato-Endocrinology. 2009;1(3):162–169.
- 11Kubba R, Bajaj AK, Thappa DM, et al. Indian Acne Alliance: clinical recommendations for acne management in India. Indian Journal of Dermatology, Venereology and Leprology. 2009;75(Suppl 1):S1–S62.
- 12Sarkar R, Garg VK. Postinflammatory hyperpigmentation in patients with skin of color. Pigmentary Disorders. 2013. (Indian skin PIH reference)
- 13Saraswat A, Lahiri K, Chatterjee M, et al. Topical corticosteroid abuse on the face: a prospective, multicenter study of dermatology outpatients. Indian Journal of Dermatology, Venereology and Leprology. 2011;77(2):160–166.
- 14Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. Journal of Clinical and Aesthetic Dermatology. 2010;3(4):24–38.
- 15Lortscher D, Admani S, Satur N, Eichenfield LF. Hormonal contraceptives and acne: a retrospective analysis of 2147 patients. Journal of Drugs in Dermatology. 2016;15(6):670–674.
- 16Bhate K, Williams HC. Epidemiology of acne vulgaris. British Journal of Dermatology. 2013;168(3):474–485.
- 17Hazarika N, Archana M. The psychosocial impact of acne vulgaris. Indian Journal of Dermatology. 2016;61(5):515–520.
- 18DDC clinical governance: all treatment content reviewed by a named dermatologist with publicly verifiable medical registration. Offline clinical approvals maintained per DDC internal governance protocol.
Get the cystic acne plan written before treatment begins
The next step is not choosing a treatment from a list. It is understanding your GAGS score, scar status, prior history, and reproductive plans, and deciding whether topical-and-antibiotic, isotretinoin, hormonal therapy, or an intralesional injection is right for the situation in front of you. That decision happens at a consultation — not on a website.
- 30–45 minute dermatologist consultation
- GAGS grading, scar-status review, written plan
- Isotretinoin candidacy discussed where appropriate
- Realistic timeline and cost — in writing
- Starting from ₹1,999 — final cost explained at consultation
Book your cystic acne consultation
By submitting this form, you agree to be contacted by our team. This form does not create a doctor-patient relationship.